Edgewise Therapeutics Receives FDA Designations for Muscle-Dystrophy Program
Edgewise Therapeutics, a clinical-stage biopharmaceutical company based in Boulder, Colorado, has recently achieved significant milestones for its EDG-5506 muscular-dystrophy program. ...
